Bevacizumab and carboplatin increase survival and asymptomatic tumor volume in a glioma model

Neuro-Oncology

Volumn 11, Issue 2, 2009, Pages 142-150

  Jahnke, Kristoph ^a   Muldoon, Leslie L ^b,c   Varallyay, Csanad G ^d   Lewin, Seth J ^b   Kraemer, Dale F ^b,c,e   Neuwelt, Edward A ^b,c,f  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^e OREGON STATE UNIVERSITY   (United States)

^f PORTLAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GLIOMA; HISTOPATHOLOGY; MALE; MONOTHERAPY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; RAT; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; CARBOPLATIN; DISEASE MODELS, ANIMAL; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; RATS; RATS, NUDE; SURVIVAL RATE; TUMOR BURDEN;

EID: 65949103172     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1215/15228517-2008-077     Document Type: Article

References (35)

1. Vredenburgh JJ, Desjardins A, Herndon JE 2nd, et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin Can- cer Res. 2007;13:1253-1259.
2. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus iri- notecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
3. Batchelor TT, Sorensen AF, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007;11: 83-95.
4. Wong ET, Brem S. Taming glioblastoma: targeting angiogenesis. J Clin Oncol. 2007;25:4705-4706.
5. Batchelor TT, Gilbert MR, Supko JG, et al. Phase 2 study of weekly irinotecan in adults with recurrent malignant glioma: final report of NABTT 97-11. Neuro-Oncology. 2004;6:21-27.
6. Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. J Neurooncol. 2002;56:183-188.
7. Cloughesy TF, Filka E, Kuhn J, et al. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regi- men. Cancer Res. 2003;97:2381-2386.
8. Friedman HS, Petros WP, Friedman AH, et al. Irinotecan therapy in adults with recurrent or progressive malignant glioma. J Clin Oncol. 1999;17:1516-1525.
9. Prados MD, Lamborn K, Yung WK, et al. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North Ameri- can Brain Tumor Consortium study. Neuro-Oncology. 2006;8:189-193.
10. Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med. 2003;49:848-855.
11. Quarles CC, Krouwer HGJ, Rand SD, Schmainda KM. Dexamethasone normalizes brain tumor hemodynamics as indicated by dynamic sus- ceptibility contrast MRI perfusion parameters. Technol Cancer Res Treat. 2005;4:245-249.
12. Preda A, Novikov V, Moglich M, et al. MRI monitoring of Avastin antiangiogenesis therapy using B22956/1, a new blood pool contrast agent, in an experimental model of human cancer. J Magn Res Imag- ing. 2004;20:865-873.
13. Neuwelt EA, Pagel MA, Kraemer DF, Peterson DR, Muldoon LL. Bone marrow chemoprotection without compromise of chemo- therapy efficacy in a rat brain tumor model. J Pharmacol Exp Ther. 2004;309:594-599.
14. Jeremic B, Shibamoto Y, Grujicic D, et al. Concurrent accelerated hyperfractionated radiation therapy and carboplatin/etoposide in patients with malignant glioma: long-term results of a phase II study. J Neurooncol. 2001;51:133-141.
15. Newton HB, Slivka MA, Stevens CL, et al. Intra-arterial carboplatin and intravenous etoposide for the treatment of recurrent and progres- sive non-GBM gliomas. J Neurooncol. 2002;56:79-86.
16. de Crespigny AJ, Howard D, D'Arceuil H, et al. Dynamic contrast- enhanced MRI of implanted VX2 tumors in rabbit muscle: comparison of Gd-DTPA and NMS60. Magn Reson Imaging. 1999;17:1297-1305.
17. Pope WB, Lai A, Nghiemphu P, Mischel P, Cloughesy TF. MRI in patients with high-grade gliomas treated with bevacizumab and che- motherapy. Neurology. 2006;66:1258-1260.
18. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature. 2000;407:249-257.
19. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK. Vascular normalization by vascular endothelial growth factor receptor 2 block- ade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res. 2004;64:3731-3736.
20. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Can- cer Cell. 2004;6:553-563.
21. Bao S, Wu Q, Sathornsumetee S, et al. Stem cell-like glioma cells pro- mote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 2006;66:7843-7848.
22. Ellis LM, Rosen L, Gordon MS. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignan- cies. Clin Adv Hematol Oncol. 2006;4:1-10.
23. Grossman SA, O'Neill A, Grunnet M, et al. Phase III study compar- ing three cycles of infusional carmustine and cisplatin followed by radiation therapy with radiation therapy and concurrent carmustine in patients with newly diagnosed supratentorial glioblastoma multi- forme: Eastern Cooperative Oncology Group Trial 2394. J Clin Oncol. 2003;21:1485-1491.
24. Huncharek M, Muscat J, Geschwind JF. Multi-drug versus single agent chemotherapy for high grade astrocytoma; results of a meta-analysis. Anticancer Res. 1998;18:4693-4697.
25. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus con- comitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987-996.
26. Vinolas N, Gil M, Verger E, et al. Pre-irradiation semi-intensive chemo- therapy with carboplatin and cyclophosphamide in malignant glioma: a phase II study. Anticancer Drugs. 2002;13:163-167.
27. Yung WK, Albright RE, Olson J, et al. A phase II study of temozolo- mide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer. 2000;83:588-593.
28. Jacobs SS, Fox E, Dennie C, Morgan LB, McCully CL, Balis FM. Plasma and cerebrospinal fluid pharmacokinetics of intravenous oxaliplatin, cisplatin, and carboplatin in nonhuman primates. Clin Cancer Res. 2005;11:1669-1674.
29. Riccardi R, Riccardi A, Lasorella A, et al. Clinical pharmacokinetics of carboplatin in children. Cancer Chemother Pharmacol. 1994;33:477-483.
30. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H. Chemo- sensitivity of glioma cells in vitro: a meta analysis. J Cancer Res Clin Oncol. 1999;125:481-486.
31. Poisson M, Pereon Y, Chiras J, Delattre JY. Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neuro- oncol. 1991;10:139-144.
32. Warnick RE, Prados MD, Mack EE, et al. A phase II study of intra- venous carboplatin for the treatment of recurrent gliomas. J Neuro- oncol. 1994;19:69-74.
33. Yung WK, Mechtler L, Gleason MJ. Intravenous carboplatin for recur- rent malignant glioma: a phase II study. J Clin Oncol. 1991;9:860-864.
34. Cloughesy TF, Prados MD, Wen PY, et al. A phase II, randomized, non-comparative clinical trial of the effect of bevacizumab (BV) alone or in combination with irinotecan (CPT) on 6-month progression free survival (PFS6) in recurrent, treatment-refractory glioblastoma (GBM) [abstract]. J Clin Oncol. 2008;26(suppl): 2010b.
35. Norden AD, Young GS, Setayesh K, et al. Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neu- rology. 2008;70:779-787.